Synapse - David Straus

Search Within

David J Straus

Results (356)

A phase '2-1-2' study of two different doses and schedules of pralatrexate, a high affinity substrate for the reduced folate carrier (RFC-1), in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies

Meeting Abstract

O'Connor, O. A.; Hamlin, P.; Portlock, C.; Moskowitz, C.; Noy, A.; Straus, D.; Dumetrescu, O.; Sarasohn, D.; Neylon, E.; Hamelers, R.; more...
Molecular Cancer Therapeutics (2007)

Fulltext@MSK | Save

High prevalence of chronic health conditions in survivors of Hodgkin lymphoma treated during adulthood

Meeting Abstract

Matasar, M. J.; Butos, J. N.; Riedel, E. R.; Ford, J. S.; Weinstock, D. M.; Oeffinger, K. C.; Straus, D. J.
Blood (2007)

Fulltext@MSK | Save

Efficacy of extracorporeal photopheresis (ECP) monotherapy in the treatment of cutaneous T cell lymphoma

Meeting Abstract

Geskin, L.; Foss, F.; Buvic, M.; Straus, D.; Horwitz, S.; Zain, J.; Kuzel, T.; Querfeld, C.; Campbell, K.; Knobler, R.
Blood (2007)

Fulltext@MSK | Save

Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma

Journal Article

Straus, D. J.; Duvic, M.; Kuzel, T.; Horwitz, S.; Demierre, M. F.; Myskowski, P.; Steckel, S.
Cancer (2007)

Fulltext@MSK | Save

How I treat mantle cell lymphoma

Journal Article

Straus, D. J.
Journal of Oncology Practice (2007)

Fulltext@MSK | Save

Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

Journal Article

O'Connor, O. A.; Hamlin, P. A.; Portlock, C.; Moskowitz, C. H.; Noy, A.; Straus, D. J.; Macgregor-Cortelli, B.; Neylon, E.; Sarasohn, D.; Dumetrescu, O.; more...
British Journal of Haematology (2007)

Fulltext@MSK | Save

Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-Hodgkin lymphoma

Journal Article

Moskowitz, C. H.; Hamlin, P. A.; Gabrilove, J.; Bertino, J. R.; Portlock, C. S.; Straus, D. J.; Gencarelli, A. N.; Nimer, S. D.; Zelenetz, A. D.
Annals of Oncology (2007)

Fulltext@MSK | Save

Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-Cell lymphomas: Results of the MSKCC phase I/II experience

Meeting Abstract

O'Connor, O. A.; Hamlin, P. A.; Gerecitano, J.; Portlock, C. S.; Noy, A.; Moskowitz, C.; Straus, D. J.; Sarasohn, D.; Dumitrescu, O.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save

Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL

Meeting Abstract

Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
Blood (2006)

Fulltext@MSK | Save

The schedule dependent combination of bortezomib (Bor) with rituximab (R), cyclophosphamide (C) and prednisone (P) produces minimal toxicity, even at relatively high doses of proteasome inhibitor, in patients with relapsed/refractory indolent B-cell lymphomproliferative disorders

Meeting Abstract

Gerecitano, J.; Portlock, C.; Noy, A.; Hamlin, P.; Moskowitz, C.; Straus, D.; Horwitz, S. M.; Palomba, M. L.; Dumitrescu, O. L.; Pappanicholaou, J.; more...
Blood (2006)

Fulltext@MSK | Save